IVD Firms Grow During 2022, but COVID-19 Revenue Dropped

Point-of-care testing services appear to be a bright spot for in vitro diagnostics

MOST MAJOR IN VITRO DIAGNOSTICS (IVD) MANUFACTURERS started strong in 2022 as their base businesses regained steam and made up for the significant falloff in COVID-19 diagnostic test revenue.  During first quarter 2022 earnings calls with investors, leaders at publicly traded IVD companies said clinical laboratories are interested in expanding test menus on technology platforms …

IVD Firms Grow During 2022, but COVID-19 Revenue Dropped Read More »

To access this post, you must purchase The Dark Report.

Comments

;

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.